In the summer of 2009 in Russian pharmacies in addition to already known to consumers suspensions Geviskon appears a welcome novelty – a natural medicine for heartburn now and Geviskon tablets! Convenient packaging innovations, 16 and 32 pieces per bundle – an optimal solution for those who care about their health and wants it to be an indispensable tool for heartburn was always at hand. The light, almost weightless, a pack of pills fit into the usual pocket, purse or glove compartment vehicle, allowing you to instantly deal with the unpleasant burning sensation in the chest. The drug is recommended for use Geviskon Scientific Society of Gastroenterologists of Russia. As well as suspension and Geviskon Geviskon Forte tablets Geviskon can be used to treat heartburn with prescription drugs. They are perfectly safe, since they consist of natural ingredients that are not absorbed and excreted in unchanged, and therefore allowed to accept even the children (12 years) and pregnant women in all trimesters. Additional information Geviskon drug, the company Reckitt Benckiser Healthcare – first in the Russian market alginate means (alge – Seaweed), which has a unique mechanism of action, which does not affect the level of acidity in the stomach. Geviskon alginate forms a neutral barrier at the surface of the stomach contents, which prevents release of acid into the esophagus. Quickly and safely gets rid of heartburn, while not affecting the digestive process.
Heartburn – a burning sensation in the chest, “the stomach”, often accompanied by a bitter taste in the mouth. Occasionally it may feel an unpleasant sensation even completely healthy people (after eating spicy foods, alcohol, or some other products), although it usually is a symptom of a number of diseases, including gastritis. According to the Central Research Institute of Gastroenterology 13.3% of Russians (about 19 million people) admit that they suffer from heartburn 1. Geviskon – Immediate release of heartburn! 1, Lazebnik LB, Bordin DS, Masharova A. Current understanding of gastroesophageal reflux disease: from Genval to Montreal.